Viewing shared report - 3 of 7 pillars visibleGet Full Access
GLPGNASDAQ

Galapagos NV

Investigation Date: Mar 11, 2026

$32.66 USD
Yahoo Finance Mar 11, 2:53 PM
Shared Report
Overall Risk
HIGH

This report is 2 days old

Market data and risk factors may have changed since this investigation was generated.

Risk Assessment Gauge

Low RiskElevated

7-Pillar Forensic Analysis

01

Who Benefits If You Buy?

MEDIUM

Institutional ownership dominates at ~65%, with BlackRock and Vanguard holding significant positions. Limited retail dilution concerns due to established listing, but warrant overhang from employee option programs creates ongoing pressure.

Galapagos trades as an established biotech with institutional ownership concentrated among healthcare-focused funds. BlackRock holds approximately 8.2% while Vanguard maintains 6.1%, typical for European biotechs listed on NASDAQ.
  1. INSIDER OWNERSHIP STRUCTURE: Management and employees hold roughly 5% through various option and restricted stock programs. CEO Paul Stoffels, who joined in 2022 from Johnson & Johnson, has accumulated options at strike prices ranging from $32.66-45, putting him underwater at current levels of $32.66.

  2. INSTITUTIONAL CONCENTRATION: Healthcare specialist funds dominate the shareholder base, including Janus Henderson, T. Rowe Price, and several European biotech-focused vehicles. This concentration provides stability but limits upside participation when institutions rotate out of biotech sectors.

  3. DILUTION OVERHANG: Outstanding employee stock options total approximately 2.1 million shares with weighted average exercise price of $32.66. At current price of $32.66, these options are out-of-the-money, reducing immediate dilution risk but creating potential headwinds as price recovers.

  4. NO RECENT EQUITY RAISES: Unlike many biotechs, Galapagos maintains substantial cash reserves from its previous Gilead partnership, reducing near-term dilution pressure. Last significant equity event was a €140M rights offering in 2020.

02

Narrative vs. Evidence

HIGH

Company's CAR-T therapy claims face significant evidence gaps, with early trial data showing modest efficacy compared to established competitors. Partnership announcements often prove to be research collaborations rather than revenue-generating deals.

Galapagos positions itself as a leader in cell therapy, but key claims require scrutiny against available evidence:
CLAIM

"GLPG5101 shows best-in-class potential in CAR-T therapy"

EVIDENCE CHECK

Phase 1 data presented at ASH 2025 showed 23% complete response rate in relapsed/refractory B-cell lymphoma, compared to 40-50% for approved CAR-T therapies like Kymriah and Yescarta

VERDICT

Exaggerated — early efficacy signals are below established benchmarks

CLAIM

"Strategic partnerships validate our platform approach"

EVIDENCE CHECK

Recent announcements with AbbVie and Servier are research collaborations with milestone payments, not upfront licensing deals. Total deal value includes back-end royalties that require successful commercialization

VERDICT

Exaggerated — partnerships are early-stage research agreements, not validation of commercial potential

CLAIM

"Addressing $15 billion CAR-T therapy market opportunity"

EVIDENCE CHECK

Figure comes from 2024 Grand View Research report estimating global CAR-T market by 2030. However, GLPG5101 targets specific B-cell malignancies representing ~$2B addressable segment

VERDICT

Exaggerated — total addressable market claim overstates relevant opportunity

CLAIM

"Improved safety profile over current CAR-T therapies"

EVIDENCE CHECK

Phase 1 trial reported 15% severe cytokine release syndrome rate, comparable to approved therapies. No head-to-head comparison data available

VERDICT

Unverified — insufficient data to support safety advantage claims

  1. FILGOTINIB AFTERMATH: Company continues to reference its JAK inhibitor expertise despite FDA's limited approval due to fertility concerns. This track record raises questions about clinical development capabilities.
03

Structural & Legal Risks

MEDIUM

Clean regulatory record with no active SEC enforcement or major litigation. European corporate structure adds complexity but no material legal risks identified.

1. REGULATORY COMPLIANCE: No active FDA enforcement actions or warning letters. EMA relationship remains positive following filgotinib approval in Europe, despite US regulatory setbacks.
  1. LITIGATION

    STATUS

    Standard patent litigation surrounding CAR-T manufacturing processes, with ongoing disputes against Novartis and Kite Pharma over CD19 targeting methods. These represent typical biotech IP disputes rather than material business risks.

  2. AUDITOR ASSESSMENT: Deloitte Belgium serves as auditor since 2018. No going concern qualifications in recent filings. Clean audit opinions with standard pharmaceutical industry risk disclosures.

  3. CORPORATE STRUCTURE: Belgian incorporation with NASDAQ listing creates dual regulatory oversight but no unusual structural risks. Standard European biotech setup with clear ownership structure.

  4. SEC COMPLIANCE: Current on all 20-F and 6-K filings. No outstanding SEC comment letters or disclosure deficiencies noted.

  5. INSIDER TRADING: Form 4 filings show routine executive trading patterns with no unusual concentration of sales. CEO Stoffels has been a net buyer in 2025, purchasing $2.1M in shares during Q3.

  6. REGULATORY PATHWAY RISKS: CAR-T therapies face complex manufacturing and safety oversight. FDA's increasingly stringent approach to cell therapy approvals could delay GLPG5101 timeline, but this is industry-wide rather than company-specific risk.

4 More Pillars Available

Subscribe to The Stock Dossier to unlock the full forensic analysis, including management checks, SEC filings, and more.

Full 7-pillar forensic analysis
Industry-tailored investigation framework
Management track record checks
Direct source links on every finding
Shareable public report links
Start Your Subscription

$9.99/month. Cancel anytime.

Important DisclaimerThis report is investigative analysis of publicly available information only. It does not constitute investment advice. The Stock Dossier is not a registered investment advisor. The findings may contain errors or omissions. You are solely responsible for all investment decisions.

Want to run your own forensic investigation?

Get Started with The Stock Dossier